永顺生物
(839729)
| 流通市值：7.30亿 | | | 总市值：25.97亿 |
| 流通股本：7682.50万 | | | 总股本：2.73亿 |
| 报告期 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 流动资产: | | | | |
| 货币资金 | 22,468,586.94 | 36,593,830.46 | 35,746,237.2 | 33,786,224.75 |
| 应收票据及应收账款 | 97,894,627.22 | 95,757,549.69 | 113,425,944.75 | 106,604,358.75 |
| 其中：应收票据 | 5,043,335.3 | 7,090,518.8 | 9,485,275.58 | 15,082,881.91 |
| 应收账款 | 92,851,291.92 | 88,667,030.89 | 103,940,669.17 | 91,521,476.84 |
| 应收款项融资 | 2,799,520 | 2,148,720 | 724,580 | - |
| 预付款项 | 167,018.99 | 681,029.07 | 89,629.5 | 250,215.63 |
| 其他应收款合计 | 2,321,688.8 | 2,175,857.96 | 2,370,437.65 | 2,652,049.47 |
| 存货 | 28,145,362.17 | 30,207,209.81 | 29,472,052.05 | 38,619,478.7 |
| 其他流动资产 | 403,600,475.54 | 382,249,735.96 | 401,846,947.89 | 328,100,861.1 |
| 流动资产平衡项目 | 0 | 0 | 0 | 0 |
| 流动资产合计 | 601,207,705.58 | 564,818,676.77 | 583,675,829.04 | 559,004,905.13 |
| 非流动资产: | | | | |
| 其他非流动金融资产 | 150,000 | 150,000 | 150,000 | 150,000 |
| 固定资产 | 165,256,048.98 | 172,677,923.1 | 173,148,832.65 | 180,468,062.67 |
| 在建工程 | 340,816.84 | 340,816.84 | 7,340,816.84 | 7,403,231.84 |
| 使用权资产 | 874,400.96 | 1,011,838.94 | 1,150,044.32 | 1,286,714.9 |
| 无形资产 | 13,346,985.35 | 14,076,126.35 | 14,646,933.35 | 5,121,150.03 |
| 长期待摊费用 | 226,666.46 | 262,455.95 | 298,245.44 | 334,034.93 |
| 递延所得税资产 | 521,100.73 | 339,323.34 | 107,034.24 | 744,964.73 |
| 其他非流动资产 | 7,086,974.55 | 6,752,495.13 | 7,284,400 | 14,835,200 |
| 非流动资产平衡项目 | 0 | 0 | 0 | 0 |
| 非流动资产合计 | 187,802,993.87 | 195,610,979.65 | 204,126,306.84 | 210,343,359.1 |
| 资产平衡项目 | 0 | 0 | 0 | 0 |
| 资产总计 | 789,010,699.45 | 760,429,656.42 | 787,802,135.88 | 769,348,264.23 |
| 流动负债: | | | | |
| 短期借款 | 1,333,273.71 | - | 27,941,220.65 | 32,595,520.17 |
| 应付票据及应付账款 | 65,674,773.51 | 57,272,487.21 | 67,702,730.04 | 57,510,681.82 |
| 应付账款 | 65,674,773.51 | 57,272,487.21 | 67,702,730.04 | 57,510,681.82 |
| 预收款项 | - | 19,800 | - | - |
| 合同负债 | 18,720,948.07 | 20,094,991.01 | 21,829,351.97 | 25,593,406.17 |
| 应付职工薪酬 | 2,980,688.13 | 6,486,046.37 | 5,258,007.64 | 2,036,361.84 |
| 应交税费 | 1,085,739.45 | 985,155.83 | 2,938,891.45 | 2,275,735.56 |
| 其他应付款合计 | 18,352,203.48 | 4,194,546.02 | 2,677,329.79 | 2,505,503.93 |
| 一年内到期的非流动负债 | 603,314.04 | 593,437.75 | 583,681.08 | 574,078.46 |
| 其他流动负债 | 425,128.44 | 463,349.77 | 428,320.46 | 548,052.18 |
| 流动负债平衡项目 | 0 | 0 | 0 | 0 |
| 流动负债合计 | 109,176,068.83 | 90,109,813.96 | 129,359,533.08 | 123,639,340.13 |
| 非流动负债: | | | | |
| 租赁负债 | 359,781.03 | 512,357.94 | 662,317.29 | 808,728.3 |
| 递延收益 | 8,723,569.72 | 9,178,251.6 | 8,821,650 | 9,371,132.07 |
| 非流动负债平衡项目 | 0 | 0 | 0 | 0 |
| 非流动负债合计 | 9,083,350.75 | 9,690,609.54 | 9,483,967.29 | 10,179,860.37 |
| 负债平衡项目 | 0 | 0 | 0 | 0 |
| 负债合计 | 118,259,419.58 | 99,800,423.5 | 138,843,500.37 | 133,819,200.5 |
| 所有者权益(或股东权益): | | | | |
| 实收资本(或股本) | 273,350,000 | 273,350,000 | 273,350,000 | 273,350,000 |
| 资本公积 | 212,161,695.23 | 221,815,515.71 | 222,590,227.52 | 222,590,227.52 |
| 减:库存股 | 15,696,000 | 27,555,836.61 | 28,821,193.58 | 28,821,193.58 |
| 盈余公积 | 68,938,593.58 | 68,938,593.58 | 64,918,823.11 | 64,918,823.11 |
| 未分配利润 | 131,996,991.06 | 124,080,960.24 | 116,920,778.46 | 103,491,206.68 |
| 归属于母公司股东权益平衡项目 | 0 | 0 | 0 | 0 |
| 归属于母公司股东权益合计 | 670,751,279.87 | 660,629,232.92 | 648,958,635.51 | 635,529,063.73 |
| 股东权益平衡项目 | 0 | 0 | 0 | 0 |
| 股东权益合计 | 670,751,279.87 | 660,629,232.92 | 648,958,635.51 | 635,529,063.73 |
| 负债和股东权益合计 | 789,010,699.45 | 760,429,656.42 | 787,802,135.88 | 769,348,264.23 |
| 公告日期 | 2025-04-28 | 2025-04-28 | 2024-10-25 | 2024-08-16 |
| 审计意见(境内) | | 标准无保留意见 | | |